anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare the title fine particles with a controlled particle size substantially in the absence of any org. solvent by localizing a polymer precursor in an aq. soln. phase enclosed in a lipid membrane and polymerizing said precursor. CONSTITUTION:A lipid (e.g., dipalmitoylphosphatidylcholine) is pref. added to an aq. soln. contg. a polymer precursor (e.g., acrylamide or N,N- methylenebisacrylamide) and dispersed therein by ultrasonic treatment to form small bubbles of the lipid membrane in said aq. soln. The polymer precursor is localized in the aq. soln. phase enclosed in the lipid membrane by removing the polymer precursor present outside the small bubbles by, e.g., dialysis or gel filtration and said precursor is polymerized pref. by irradiation with a radiation.
Atazanavir has been shown to increase tenofovir concentrations [See Clinical Pharmacology (12.3)]. The mechanism of this interaction is unknown. Patients receiving atazanavir and VIREAD should be monitored for VIREAD-associated adverse reactions. VIREAD should be discontinued in patients who develop VIREAD-associated adverse reactions.

VIREAD decreases the AUC and Cmin of atazanavir [See Clinical Pharmacology (12.3)]. When coadministered with VIREAD, it is recommended that atazanavir 300 mg is given with ritonavir 100 mg. Atazanavir without ritonavir should not be coadministered with VIREAD.
Background: Incompetent perforating vein (IPV) is one of the important causes of persistent venous ulcers of lower extremities and recurrence after operation of varices which is a hot button issue worth discussing in clinical practice. Minimally invasive surgery has become the trend of IPVs' treatment. Currently, sclerotherapy can be performed to treat incompetent perforating veins, which showed a 90% occlusion rate after three or fewer sessions, the recurrence was present nearly 1/3 of cases. While electrocoagulation has a reliable effect on the closure of incompetent perforating veins and simplify treatment. No comparative studies of different PAPS modalities are currently available. Therefore, this study aimed to compare the efficacy of punctured electrocoagulation and sclerotherapy in the treatment of incompetent perforating veins. Methods:This study is a multicenter, randomized controlled trial. We will recruit 84 patients with IPVs from five hospitals. Moreover, these patients will be randomized to either the experimental group (electrocoagulation) or the control group (sclerotherapy). The primary outcome is incompetent perforating veins occlusion rate in the 12th month. Secondary outcomes are quality of life scale survey results (CEAP classification, VCSS score, CIVIQ-14 score), skin ulcer recurrence rate, deep venous Thrombosis, hemorrhage, all-cause mortality, and other vascular events and serious complications.Discussion:This study will provide reliable, evidence-based clinical evidence for the efficacy of electrocoagulation therapy for incompetent perforating veins.
PURPOSE: Disparities in cervical cancer screening, incidence, and mortality exist in the United States. Cervical cancer incidence and mortality rates in Texas are 20% and 32% higher, respectively, than national averages. Within Texas, these rates are significantly higher among non-Hispanic (NH) Black and Hispanic women. Cervical cancer screening uptake is lower among NH Black and Hispanic women (72.9% and 75.9%, respectively) compared with White women (85.5%) in Texas.
METHODS: During March-August 2023, we conducted a pilot study that offered culturally competent education and human papillomavirus (HPV) self-sampling kits to women in two public housing projects in Houston, TX, that have predominantly NH Black or Hispanic residents. Among those eligible for cervical cancer screening, 35% (n = 24) of the NH Black and 34% (n = 16) of the Hispanic women were found to be underscreened per the US Preventive Services Task Force Guideline. We recruited 40 (24 NH Black and 16 Hispanic) eligible women for our study. The study was approved by the MD Anderson institutional review board and registered with ClinicalTrials.gov (NCT04614155-March 11, 2020).
RESULTS: Seventy-five percent of the NH Black and 87% of the Hispanic participants completed the HPV self-sampling procedures per protocol. Samples of 17% NH Black and 12% Hispanic participants showed a performance error. Overall, cervical cancer screening uptake improved from 65% to 91% among NH Black and from 66% to 96% among Hispanic participants.
CONCLUSION: Culturally competent education and HPV self-sampling resulted in remarkable improvement in cervical cancer screening uptake among underscreened NH Black and Hispanic women residents of Houston public housing projects. Implementing this strategy could significantly reduce cervical cancer incidence and mortality among similar populations in the United States and globally.
Medication waste may be caused by medication oversupply; however, the degree of medication oversupply in Japan is unclear. This study aimed to quantify the degree of oversupply of chronic disease medications per patient, the proportion of oversupplied patients, and the excess days and costs of the oversupplied medications in Japan. This retrospective nationwide cohort study using a large insurance claims database from Japan was conducted in patients aged ≥55 years who received one or a combination of the following five classes of medications dispensed in FY 2019: third-generation calcium antagonists, angiotensin 2 receptor blockers, statins, dipeptidyl peptidase-4 inhibitors, and biguanides. Medications with the same ingredient having the same specification were treated as the same medication. Medication oversupply was defined as a medication possession ratio (MPR) during persistence >1.0. The proportions of oversupplied patients and excessively oversupplied patients with ≥30 excess days/year were approximately 16 and 1-2% for all drug classes, respectively. Three-quarters of the oversupplied patients had fewer excess day (≤14/year), and the median oversupplied medication cost was less than 1000 yen/year for all classes. However, there was a patient with oversupplied medication estimated as 983 excess days per year and a patient with oversupplied medication costs of nearly 90000 yen per year. Using the MPR and excess days as indicators, it is necessary to accelerate estimation of the oversupply per patient, as well as the development of patient intervention strategies and a national system to reduce medication oversupply.
The invention provides an anti-flue and pidemic disease-avoiding sachet and a preparation method thereof. According to the technical scheme, the pharmacological effects of multiple pharmaceutical ingredients serving as incense materials are found out through experiment measures, and on this basis, a pharmaceutical composition and the composition proportion thereof are determined. By matching all medicinal materials in the anti-flue sachet, the effects of killing and inhibiting bacteria, purifying air, reducing infection sources of surrounding air to an infection threshold value and improving human immunity are achieved, and therefore the effects of effectively preventing flus, avoiding pidemic diseases and shortening cold cycle are achieved. The sachet is lasting in effect and convenient to carry and is an advantageous choice for children, old people and people with low immunity. On this basis, formulation ingredients are further optimized, by adding the ingredients such as bitter orange, gynurae segeti and herba rhodiolae, the volatilization characteristic of drugs can be improved, and the drug efficacy duration is further prolonged. According to the anti-flue and pidemic disease-avoiding sachet and the preparation method thereof, a good technical effect is achieved through innovative technical improvement, and meanwhile the cost is low, and implementation is easy; therefore, the anti-flue and pidemic disease-avoiding sachet and the preparation method thereof have a good application prospect.
Heart failure (HF) is increasing in prevalence and incidence and is the most common reason for hospital admissions of patients over the age of 65. Therapy for HF has evolved over the last two decades. Cardiac resynchronization therapy (CRT) is a therapy that attempts to resynchronize the sequence of ventricular contraction in heart failure (HF) patients with left ventricular (LV) systolic dysfunction and ventricular dyssynchrony. CRT is achieved by stimulating both RV and LV together, synchronized to right atrial excitation to achieve atrio-ventricular synchrony. Clinical trials have demonstrated that CRT reduced heart size, improved survival and reduced HF hospitalization in mild to advanced HF patients. This knowledge translated to a change in practice guidelines and the adoption of CRT into clinical practice benefitting many HF patients CRT is now an important state-of-the-art therapy for HF patients with LV systolic dysfunction, low LVEF, and prolonged QRS duration in sinus rhythm, since the vast majority of the CRT clinical research was performed in patients in sinus rhythm. However, in the \~25% of HF patients with permanent atrial fibrillation (AF), the effectiveness of CRT is not clear. It is therefore timely to address the question of whether the addition of CRT to optimal HF treatment, rate control and an ICD improves cardiac outcomes in individuals with heart failure (HF) and permanent atrial fibrillation (AF). The outcomes will be measured by a hierarchy of all-cause mortality, HF events, Left Ventricular Ejection Fraction (LVEF) and improvement in Quality of Life (QoL) in patients with permanent AF, mild to moderate HF, left ventricular (LV) systolic dysfunction, and prolonged QRS duration, when compared to implantable cardioverter defibrillator (ICD) therapy alone.

Objectives: To determine whether cardiac resynchronization therapy will improve cardiac outcomes for heart failure patients with permanent atrial fibrillation, mild to moderate heart failure, left ventricular systolic dysfunction, and prolonged QRS duration, when compared to implantable cardioverter defibrillator (ICD) therapy alone.

Methods: This is a multi-centre randomized controlled trial of two treatment groups. The patients, primary physicians and the heart failure caregivers will be blinded to the treatment allocation. The device follow-up caregivers will not be blinded. Patients with NYHA Class II and III HF symptoms, LVEF HF ≤ 35%, permanent AF, on optimal medical therapy and QRS durations ≥ 130 ms when the QRS morphology is LBBB, or QRS durations ≥ 150 ms when the QRS morphology is non-LBBB, or Paced QRS will be included in the trial. Patients should be suitable candidates for either of the 2 treatment strategies. There will be 200 patients randomized in 1:1 ratio to two groups: 1) ICD-CRT, 2) ICD only. All patients will undergo baseline clinical evaluation, echocardiogram measurements, quality of life assessment, medication assessment, and 6-minute walk distance.. The patients will be followed at 1 month, 3 months, 6 months and then every 6 months.
All subjects received SB204 4% once daily (QD) in this open label study. Subjects assigned to SB204 4% QD in the parent study (NI-AC301/302) continued to receive SB204 for 40 more weeks. Subjects assigned to Vehicle Gel in the parent study (NI-AC301/302) received SB204 4% QD in this open label study.
The invention discloses a Chinese medicinal external composition for curing gynecological diseases and a preparation method thereof. The composition is prepared from amur corktree bark, hairyvein agrimonia herb and bud, common cnidium fruit, climbing groundsel herb, dried alum and borneol in a certain ratio. The composition is prepared into clinically acceptable external formulations such as suppository, external capsules, gel, ointments, vaginal tablets, vaginal effervescent tablets, vaginal films, lotion, aerosol, foaming agent and the like by a pharmaceutical conventional method. The composition has good curative effects on cervical erosion, gynecological inflammation, and urinary tract infection of women. The composition is prepared into an external preparation and is not orally administrated so as to avoid first-pass effect on liver and physiological screening effects of gastrointestinal tracts and reduce untoward effect. The external preparation can directly act on afflicted parts, and has the advantages of strong pertinence, general actions through skin and mucosa, quick medicinal absorption, less interference to internal environment of body, non-traumatic treatment mode, simple operation, good safety of clinical use, high cure rate, base strengthening of Chinese medicaments, and less side effect. The composition can effectively eliminate cause of diseases, can safely and effectively cure diseases under guidance of doctors and is easy to popularize.
Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of Remifentanil hydrochloride for injection slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.2)]   
  
Of the total number of subjects in clinical studies of Remifentanil hydrochloride for injection, 486 were 65 and over (age range 66 to 90 years). While the effective biological half-life of remifentanil is unchanged, elderly patients have been shown to be twice as sensitive as the younger population to the pharmacodynamic effects of remifentanil. The recommended starting dose of Remifentanil hydrochloride for injection should be decreased by 50% in patients over 65 years of age [see Clinical Pharmacology (12.3) and Dosage and Administration (2.2)]. Titrate the dosage of Remifentanil hydrochloride for injection slowly in geriatric patients. [See Warnings and Precautions (5.5).] 

The clearance of remifentanil is reduced (approximately 25%) in the elderly (> 65 years of age) compared to young adults (average 25 years of age). However, remifentanil blood concentrations fall as rapidly after termination of administration in the elderly as in young adults.  
  
This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Optical genome mapping (OGM) is a new DNA-based technology which provides comprehensive examination of the entire genome. We report two patients who presented with splenomegaly and leukocytosis with lymphocytosis including villous lymphocytes. Neither patient had lymphadenopathy. Bone marrow evaluation showed involvement by small B-cell lymphoma in a sinusoidal and interstitial distribution, and immunophenotypic analysis showed that the neoplastic cells were positive for B-cell markers and cyclin D1 but were negative for SOX11 and CD5. Initially, the clinicopathologic features in both patients were thought to be suspicious for hairy cell leukemia variant or splenic marginal zone lymphoma. However, OGM detected CCND1 rearrangement: t(2;11)/IGK::CCND1 in one case and t(11;14)/IGH::CCND1 in the other case. These cases illustrate the valuable role OGM can play in establishing the diagnosis of MCL. Case 1 also contributes to the paucity of literature on the rare occurrence of IGK::CCND1 in MCL.
Inflammation is a highly dynamic process with immune cells that continuously interact with each other and parenchymal components as they migrate through tissue. The dynamic cellular responses and interaction patterns are a function of the complex tissue environment that cannot be fully reconstructed ex vivo, making it necessary to assess cell dynamics and changing spatial patterning in vivo. These dynamics often play out deep within tissues, requiring the optical focus to be placed far below the surface of an opaque organ. With the emergence of commercially available two-photon excitation lasers that can be combined with existing imaging systems, new avenues for imaging deep tissues over long periods of time have become available. We discuss a selected subset of studies illustrating how two-photon microscopy (2PM) has helped to relate the dynamics of immune cells to their in situ function and to understand the molecular patterns that govern their behavior in vivo. We also review some key practical aspects of 2PM methods and point out issues that can confound the results, so that readers can better evaluate the reliability of conclusions drawn using this technology.
Therapeutic compositions for injection comprise finely divided micro-particles of a metabolisable substance having an active drug adsorbed thereon, said micro-particles containing said drug being encapsulated in a metabolisable film-forming substance and said encapsulated micro-particles being suspended in a physiologically acceptable or non-toxic liquid carrier.  The carrier may be an oil or saline solution, and when the former is used, the suspension may subsequently be emulsified in water; alternatively, the carrier may be a secondarily active substance, e.g. an anti-histaminic agent, or an anti-serium.  The particles on which the drug is adsorbed are generally those of starch, but milled particles of dry amino acids or nucleic acids are also suitable.  Suitable encapsulating agents include methyl, ethyl and hydroxyethyl celluloses, and low molecular weight polyethylene, polypropylene, polymethyl methacrylate, polyethyl methacrylate and polyethyl acrylate.  The invention is particularly applicable for administering drugs which are normally likely to produce adverse side-effects; such drugs include antigens, anti-allergic agents, e.g. anti-histaminic agents, toxins and allergenic materials, and extracts of pollen.
The invention discloses a traditional Chinese medicine used for treating stomach, intestines and faucitis at the same time, which is made from the following raw materials in equant proportion: fiveleaf gynostemma herb, leech and liquorice. The dosage form has herb tea dosage form, soakage adsorption dosage form and medicinal tea dosage form. The medicine has marked effect in treating gastroenteritis, stomach intestine distending pain, stomach variola, faucitis, throat swelling and pain, and indigestion, etc. The invention has the advantages of scientific proportion, good safety, natural medicine, without toxic and side effects, small dose, stable property, distinguished performance, quick anti-inflammation and acesodyne, perfect effect, perfect mouthfeel, little sweet, easy to accept, convenient for taking. The invention can be made into herb tea dosage form, soakage adsorption dosage form and medicinal tea dosage form, wherein, the later two types can be triturated and be carried conveniently. The applicability of the invention is wide and the invention has treat effect to stomach intestine and faucitis swelling and pain. The prescription is easy, the cost is low, and the medicine resource is wide and available.
In chronic myeloid leukemia, the identification of early molecular predictors of stable treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation is challenging. The predictive values of residual disease (BCR::ABL1 quantification) at month 3 and 6 and more recently, BCR::ABL1 transcript halving time (HT) have been described, but no study compared the predictive value of different early parameters. Using a real-world cohort of 408 patients, we compared the performance of the EUTOS long-term survival (ELTS) score, BCR::ABL1 HT, and residual disease at month 3 and 6 to predict the molecular response, achievement of the TKI discontinuation criteria, and TFR maintenance. The performances of BCR::ABL1 HT and residual disease at month 3 were similar. Residual disease at month 6 displayed the best performance for predicting the optimal response (area under the ROC curve between 0.81 and 0.92; cut-off values: 0.11% for MR4 at month 24 and 0.12% for MR4.5 at month 48). Conversely, no early parameter predicted reaching the TKI discontinuation criteria and TFR maintenance. We obtained similar results when patients were divided in subgroups by first-line treatment (imatinib vs. second-generation TKI [2G-TKI]). We identified a relationship between ELTS score, earlier milestones and TFR maintenance only in the 2G-TKI group. In conclusion, this first comparative study of early therapeutic response parameters showed that they are excellent indicators of TKI efficacy (BCR::ABL1 transcript reduction) and best responders. Conversely, they did not predict the achievement of the TKI discontinuation criteria and TFR maintenance, suggesting that other parameters are involved in TFR maintenance.
PROBLEM TO BE SOLVED: To provide the subject new sequence having a specific nucleotide sequence, giving an expression product uninfluential to the interaction of Gβ and Cdc24p, etc., and useful for medical use or e.g. for the production of pharmaceuticals exerting influence upon the proliferation behavior of cell. SOLUTION: This sequence is a new nucleotide sequence of the formula or its derivative or homologue giving an expression product essentially free from influence upon the interaction of Gβ and Cdc24p or its homologue usually capable of bonding therewith. It is useful for medical use and e.g. for the production of pharmaceuticals exerting influence upon the proliferation behavior of cell. The nucleotide sequence can be produced from a DNA containing a gene of cell division cycle molecule Cdc24 of yeast having remarkable homology to a protooncogene Dbl by preparing a library in a plasmid vector suitable for phenotypic screening of yeast by PCR and screening the library.
Acute respiratory distress syndrome (ARDS) is the most extreme form of acute lung injury (ALI) that results in a loss of lung function and structure. Vascular endothelial growth factor (VEGF), a protein critical for lung development that is found in the thin layer of liquid lining the inner surface of the lung air sacs, is believed to play a key role in the development of ARDS. During ARDS/ALI, VEGF markedly increases the permeability of the cells lining the inner surface of blood vessels in the lungs, which leads to an accumulation of fluid in the lungs (pulmonary edema), a characteristic of ARDS/ALI. Thus, anti-VEGF therapies offer a unique approach to treat this potentially fatal disorder. Bevacizumab (Avastin ®), an anti-VEGF medication, has been shown to be effective in inhibiting pulmonary edema caused by VEGF over-expression in an animal model.

This study will establish the usefulness and effectiveness of a singe dose of Bevacizumab administered intravenously (through the vein) in reducing the incidence of ARDS in individuals with severe sepsis (a condition characterized by an inflammatory response by the immune system throughout the whole body caused by infection) who are at high risk for the development of ARDS. All study participants will be randomized to receive placebo, bevacizumab 5 mg/kg or bevacizumab 10 mg/kg as a single intravenous dose in a double-blinded fashion in addition to traditional sepsis treatment.